<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRAVASTATIN</span><br/>(pra-vah-stat'in)<br/><span class="topboxtradename">Pravachol<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span>; <span class="classification">hmg-coa reductase inhibitor (statin)</span><br/><b>Prototype: </b>Lovastatin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg, 80 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes cholesterol biosynthesis.
         HMG-CoA reductase inhibitors (statins) increase serum HDL cholesterol levels and decrease serum LDL cholesterol, VLDL cholesterol,
         and plasma triglyceride levels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is effective in reducing total and LDL cholesterol in various forms of hypercholesterolemia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypercholesterolemia (alone or in combination with bile acid sequestrants) and familial hypercholesterolemia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pravastatin; active liver disease or unexplained elevated liver function test; pregnancy (category X),
         lactation. Safety and efficacy in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Alcoholics, history of liver disease; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperlipidemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1080 mg q.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>813 y,</i> 20 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to meals.</li>
<li>Give in the evening.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain, vomiting, constipation, flatulence, heartburn, transient elevations in serum liver transaminase
      levels. <span class="typehead">Other:</span> Fatigue, rhinitis, cough, transient elevations in CPK. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase PT when administered with <b>warfarin</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract; 17% reaches systemic circulation. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Peak:</span> 4 wk. <span class="typehead">Distribution:</span> 4355% protein bound; does not cross bloodbrain barrier; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver; has no active metabolites. <span class="typehead">Elimination:</span> 20% of dose excreted in urine, 71% in feces. <span class="typehead">Half-Life:</span> 1.82.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform liver function tests at start of therapy and then at 12 wk. If normal at 12 wk, may change to semiannual
            monitoring. Monitor cholesterol levels throughout therapy.
         </li>
<li>Monitor coagulation studies with patients receiving concurrent warfarin therapy. PT may be prolonged.</li>
<li>Monitor CPK levels if patient experiences unexplained muscle pain.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, to physician promptly.</li>
<li>Report signs of bleeding to physician promptly when taking concomitant warfarin therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>